Apatinib in Neoadjuvant Therapy for Patients With Breast Cancer

Inclusion Criteria: 1. breast invasive carcinoma diagnosed by core needle biopsy, without previous treatments for breast cancer; 2. with the molecular subtypes of triple-negative, HER2+ or Luminal B, confirmed by immunohistochemistry; 3. breast cancer within stage IIb-IIIc, planned to receive neoadjuvant therapy; 4. women aged from 18 to 70 years old; 5. required to have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1; 6. left ventricular ejection fraction (LVEF) greater than 55% without clinical symptoms or signs of heart failure; 7. Adequate bone marrow, with white blood cell ≥4.0×109 /L，neutrophils ≥2.0×109 /L, platelet ≥100×109 /L, hemoglobin ≥ 90 g/L； 8. Serum creatinine ranges from 44 to 133 mol/L; 9. Glutamic pyruvic transaminase and Glutamic-oxalacetic Transaminase ≤2 times to superior limit of normal value; 10. bilirubin ≤ superior limit of normal value; 11. Expected survival ≥ 12 months; 12. pregnancy tests must be negative, and the couples of patients should agree to use effective contraception during treatment and the following one year; 13. approved by the institutional ethnics committee of the Fourth Hospital of Hebei Medical University, with signature to the Informed consent. Exclusion Criteria: 1. severe systemic infection; 2. being allergic or intolerant to apatinib, paclitaxel, cisplatin; 3. having received any testing drugs, radiotherapy or other chemotherapy drugs within 30 days before being enrolled in this trial; 4. uncontrolled hypertension, severe heart function; 5. researchers believe that participating in the test does not meet the best interests of the patients (e.g. cause adverse health) or may interfere with the evaluation of response.